Item 8.01. Other Events.

On January 18, 2022, Nabriva Therapeutics plc (the "Company") announced that it adjourned, without conducting any business, the Company's extraordinary general meeting of shareholders (the "EGM"), on Tuesday, January 18, 2022 until Thursday, March 24, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021.

The original record date for determining shareholders entitled to vote at the EGM was November 19, 2021. In connection with the reconvening of the EGM on March 24, 2022, the Company has established the close of business on February 18, 2022 as the new record date for determining shareholders entitled to vote at the EGM or any adjournments or postponements thereof.

© Edgar Online, source Glimpses